ISSN 1016-5169 | E-ISSN 1308-4488
pdf
The Effects of Iron Replacement on Functional Capacity in Patients with Group 1 and Group 4 Pulmonary Hypertension [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2022; 50(7): 492-497 | DOI: 10.5543/tkda.2022.22343

The Effects of Iron Replacement on Functional Capacity in Patients with Group 1 and Group 4 Pulmonary Hypertension

Dursun Akaslan1, Emre Aslanger1, Halil Ataş1, Batur Gönenç Kanar1, Derya Kocakaya2, Bedrettin Yıldızeli3, Bülent Mutlu1
1Department of Cardiology, Marmara University, Pendik Training and Research Hospital, İstanbul, Turkey
2Department of Pulmonology, Marmara University, Pendik Training and Research Hospital, İstanbul, Turkey
3Department of Thoracic Surgery, Marmara University, Pendik Training and Research Hospital, İstanbul, Turkey


OBJECTIVE
Abnormal iron handling complicates pulmonary hypertension and causes functional limitation and poor outcomes. Although preliminary results in group 1 pulmonary hypertension patients support the use of iron replacement, whether this applies to other PH subgroups is not known.


METHODS
A total of 58 patients with an established diagnosis of group 1 or 4 pulmonary hypertension, who had serum ferritin of <100 ng/mL or 100-300 ng/mL in combination with a transferrin saturation <20% and received 500-1000 mg of ferric carboxymaltose, were included in the study. The change in ferritin levels and transferrin saturation was calculated at 12- and 24-week follow-up. A six-minute walk test is undertaken at the first, 12-week, and 24-week follow-up visits.


RESULTS
In group 1 pulmonary hypertension patients, ferritin levels increased from 14 ng/mL to 133 and 90 ng/mL at 12- and 24-week, respectively (P <.001 for both). In group 4 pulmonary hypertension patients, ferritin levels increased from 22.1 ng/mL to 145 and 88.9 ng/mL at 12 and 24 weeks, respectively (P <.001 for both). The 6-minute walk test distances were 356, 412, and 350 m in group 1 pulmonary hypertension patients and 260, 315, and 290 m in group 4 pulmonary hypertension patients. Although the difference between baseline and 12-week 6-minute walk test was significant in both groups (P <.001 for both), this difference was lost at 24-week.


CONCLUSION
Our study indicates that there is no difference in response to iron replacement in patients with group 1 and group 4 pulmonary hypertension patients, in terms of treatment success and functional status.

Keywords: Anemia, chronic thromboembolic pulmonary hypertension, ferric carboxymaltose, pulmonary arterial hypertension, pulmonary hypertension

How to cite this article
Dursun Akaslan, Emre Aslanger, Halil Ataş, Batur Gönenç Kanar, Derya Kocakaya, Bedrettin Yıldızeli, Bülent Mutlu. The Effects of Iron Replacement on Functional Capacity in Patients with Group 1 and Group 4 Pulmonary Hypertension. Turk Kardiyol Dern Ars. 2022; 50(7): 492-497

Corresponding Author: Dursun Akaslan
Manuscript Language: English


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.